Background: The Food Allergy Quality-of-Life Questionnaire-Parent Form (FAQLQ-PF) is widely used to assess food allergy-specific health-related quality of life (FAQL), but cannot be used directly in cost-utility analyses, which require health state utility (HSU) scores. Currently, limited evidence is available regarding the HSU of food-allergic children/adolescents. This study aimed to develop mapping algorithms from the FAQLQ-PF onto HSU scores generated by generic, preference-based, health-related quality-of-life (HRQL) instruments.

Methods: Caregivers of children aged 7 to 17 years with a clinician diagnosis of IgE-mediated food allergy, recruited via Allergy & Anaphylaxis Australia, completed an online FAQLQ-PF questionnaire and proxy generic preference-based pediatric instruments (Assessment of Quality of Life [AQoL]-6D and Child Health Utility 9D [CHU9D]). Optimal statistical methods were based on series of goodness-of-fit statistics.

Results: Mean FAQLQ-PF total score, AQoL-6D, and CHU9D utility scores of 238 food-allergic children/adolescents were 3.49 (SD: 1.41), 0.78 (SD: 0.22), and 0.74 (SD: 0.22), respectively. The Spearman correlation coefficients of FAQLQ-PF with AQoL-6D and CHU9D were rho = -0.56 and rho = -0.45, respectively. Optimal mapping algorithms were generated from selected FAQLQ-PF items, mapped onto AQoL-6D or CHU9D utility scores, with AQoL-6D demonstrating better performance.

Conclusions: This study generated mapping algorithms to help facilitate the use of FAQLQ-PF for cost-utility analyses, which are essential for health economic evaluation. External validation of the reported mapping algorithms is warranted.

Dianne E Campbell is a part‐time employee of DBV Technologies and reported receiving grant support from National Health and Medical Research Council of Australia and personal fees from Allergenis, Westmead Fertility Centre, and Financial Markets Foundation for Children.Gang Chen has no conflicts to disclose.Audrey DunnGalvin has received research grants from Aimmune Therapeutics, National Children's Research Centre Ireland, DBV Technologies, and Food Allergy Research and Resource Program, as well as other research support from SafeFood Ireland, and has served as a consultant and/or advisory board member for Aimmune Therapeutics, Atlantia Clinical Trials in Food Ireland, and Anaphylaxis Ireland.Matthew Greenhawt has received past support by grant #5K08HS024599‐02 from the Agency for Healthcare Research and Quality; is a consultant for Aquestive; is a member of physician/medical advisory boards for DBV Technologies, Sanofi/Regeneron, Genentech, Nutricia, Novartis, Aquestive, Allergy Therapeutics, Pfizer, US World Meds, Allergenis, Aravax, and Prota; is a member of the scientific advisory council for the National Peanut Board; is the senior associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy Practice Parameters. He has received an honorarium for lectures from ImSci, Connecticut Children's Medical Center, and Med Learning Group.Marcus Shaker has a family member who is CEO of Altrix Medical, is a member of the Joint Taskforce on Allergy Practice Parameters, and serves as a member of the editorial boards of theJournal of Allergy and Clinical Immunology:In Practice, theAnnals of Allergy,Asthma,and Immunology, and theJournal of Food Allergy.